Economic analysis of aflibercept in wet age-related macular degeneration
- 作者: Gerasimova K.V1, Derkach E.V2, Loskutov I.A3
-
隶属关系:
- First Moscow State Medical University
- Russian Presidential Academy of National Econommy and Public Administration
- Clinical and research center of OJSC Russian Railways
- 期: 卷 9, 编号 2 (2016)
- 页面: 30-35
- 栏目: Articles
- URL: https://journals.rcsi.science/ov/article/view/3031
- DOI: https://doi.org/10.17816/OV9230-35
- ID: 3031
如何引用文章
详细
作者简介
Kseniya Gerasimova
First Moscow State Medical UniversityPhD, assistant professor
Elena Derkach
Russian Presidential Academy of National Econommy and Public AdministrationPhD, leading scientific researcher
Igor Loskutov
Clinical and research center of OJSC Russian RailwaysDMedSc, head of ophthalmology department
参考
- Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11:67-115. doi: 10.1076/opep.11.2.67.28158.
- Pece A, Azzolini C, Parodi MB, et al. Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab. Expert Rev. Ophthalmol. 2012;7(3):219-225. doi: 10.1586/eop.12.24.
- Белехова С.Г., Астахов Ю.С. Роль генетически детерминированных факторов в патогенезе возрастной макулярной дегенерации // Офтальмологические ведомости. - 2015. - Т. 8. - № 4. - С. 30-39. [Belekhova SG, Astakhov YS. The role of genetically determined factors in age-related macular degeneration pathogenesis. Ophthalmology Journal. 2015;8(4):30-39. (In Russ).] doi: 10.17816/OV2015430-39.
- Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640-2. doi: 10.1001/archopht.1984.01040031330019.
- Инструкция по применению лекарственного препарата для медицинского применения Луцентис (ранибизумаб) [электронный ресурс]. URL: http://www.grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=86232&t= [Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Lutsentis (ranibizumab) [elektronnyy resurs]. URL: http://www.grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=86232&t= (In Russ).]
- Krebs I, Glittenberg C, Ansari-Shahrezaei S, et al. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 2013;97:1443-1446. doi: 10.1136/bjophthalmol-2013-303513.
- Инструкция по применению лекарственного препарата для медицинского применения эйлеа [электронный ресурс]. URL: http:// www.grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=1396540&t= [Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Eylea [elektronnyy resurs]. URL:http://www.grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=1396540&t= (In Russ).]
- Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006.
- Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011.
补充文件
